InpharmD

Read InpharmD's clinical summaries on newly approved FDA medications for the month of July:

AHZANTIVE® (aflibercept-mrbb)
https://inpharmd.com/blogs/new-fda-approval-ahzantive-aflibercept-mrbb

PYZCHIVA® (ustekinumab-ttwe)
https://inpharmd.com/blogs/new-fda-approval-pyzchiva-ustekinumab-ttwe

KISUNLA™ (donanemab-azbt)
https://inpharmd.com/blogs/new-fda-approval-kisunla-donanemab-azbt

EPYSQLI™(eculizumab-aagh)
https://inpharmd.com/blogs/new-fda-approval-epysqli-eculizumab-aagh

FEMLYV™ (ethinyl estradiol and norethindrone acetate)
https://inpharmd.com/blogs/new-fda-approval-femlyv-ethinyl-estradiol-and-norethindrone-acetate

We have four new FDA approval updates this week! Read the InpharmD summaries on our blog, links below.

1. Capvaxive™ - https://inpharmd.com/blogs/new-fda-approval

2. Vigafyde™ - https://inpharmd.com/blogs/new-fda-approval-vigafyde-vigabatrin-oral-solution

3. Yimmugo® - https://inpharmd.com/blogs/new-fda-approval-yimmugo-immune-globulin-intravenous-human-dira-liquid-for-intravenous-injection

4. Sofdra™ - https://inpharmd.com/blogs/new-fda-approval-sofdra-sofpironium

The FDA recently approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna.

Read the InpharmD summary here: https://inpharmd.com/blogs/new-fda-approval-mresvia-respiratory-syncytial-virus-vaccine-mrna

The Food and Drug Administration (FDA) recently approved YESAFILI™(aflibercept-jbvf) and OPUVIZ™(aflibercept-yszy) as interchangeable biosimilars to Eylea (aflibercept).

Both drugs are used to treat neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Read InpharmD's clinical summary here: https://inpharmd.com/blogs/new-fda-approvals-yesafili-aflibercept-jbvf-and-opuviz-aflibercept-yszy